For Healthcare Professionals
Congress Materials and Manuscript Publications
This site is intended as an educational resource for healthcare providers practicing in the United States. It may include information about products or uses that have not been approved by the U.S. Food and Drug Administration.
Congress Materials
November 2024
American College of Rheumatology (ACR) Convergence
Efficacy, Safety, Pharmacokinetics of Anti-CD40 Antibody Abiprubart in Patients with Rheumatoid Arthritis: a Phase 2, Randomized, Placebo-Controlled 12-week-treatment Proof-of-Concept Study
August 2024
European Society of Cardiology (ESC) Annual Congress 2024
Multi-Year Recurrent Pericarditis Disease Duration in Italian Patients: Clinical Outcomes After Cessation of Long-Term IL-1 Pathway Inhibition Provide Insights for Chronic Management
Increased Adoption of IL-1 Pathway Inhibition and the Steroid-Sparing Paradigm Shift: Temporal Trends in Recurrent Pericarditis Treatment from the RESONANCE Patient Registry
June 2024
European Alliance of Associations for Rheumatology (EULAR)
Efficacy, safety, and pharmacokinetics of anti-CD40 antibody abiprubart (KPL-404) in patients with rheumatoid arthritis: a phase 2, randomized, placebo-controlled, 12-week-treatment, proof-of-concept study
April 2024
American College of Cardiology (ACC) Annual Congress
Rilonacept Utilization in a Steroid-Sparing Paradigm for Recurrent Pericarditis: Real-World Evidence Demonstrating Increased Adoption
November 2023
American Heart Association (AHA) Scientific Sessions
Cardiac Magnetic Resonance Imaging Paralleled Recurrent Pericarditis Clinical Response to Rilonacept Treatment Over 18 Months: a RHAPSODY Subgroup Analysis
March 2023
American College of Cardiology (ACC) Annual Congress
Baseline demographics and disease characteristics of patients enrolled in registry of the natural history of recurrent pericarditis in pediatric and adult patients (RESONANCE)
November 2022
American Heart Association (AHA) Scientific Sessions
Absence of pericarditis recurrence in rilonacept-treated patients with COVID-19 and mRNA vaccinations: experience from phase 3 RHAPSODY long-term extension
Prolonged rilonacept treatment in RHAPSODY long-term extension provided persistent reduction of pericarditis recurrence risk
November 2022
American College of Rheumatology (ACR) Convergence
Dose-dependent suppression of T cell-dependent antibody response in healthy volunteers by KPL-404, an anti-CD40 monoclonal antibody, supports phase 2 study in patients with rheumatoid arthritis
April 2022
American College of Cardiology (ACC) Annual Congress
Neutrophil to lymphocyte ratio for tracking inflammation and recurrence in patients with recurrent pericarditis: post hoc assessment of a phase 3 trial, RHAPSODY
Real-world experience and unmet needs in the current management of recurrent pericarditis: a physician survey and medical chart review
November 2021
American College of Rheumatology (ACR) Convergence
Safety, tolerability, pharmacokinetics, receptor occupancy, and suppression of T-cell-dependent antibody response in a phase 1 study with KPL-404, an anti-CD40 monoclonal antibody
October 2021
Academy of Managed Care Pharmacy (AMCP) Annual Meeting
Characterization of recurrent pericarditis in Medicare Advantage patients: disease burden, pharmacotherapy, and outcomes
June 2021
European Alliance of Associations for Rheumatology (EULAR)
Mavrilimumab improves outcomes in phase 2 trial in non-mechanically-ventilated patients with severe COVID-19 pneumonia and systemic hyperinflammation
Recent Manuscript Publications
(Your ability to access these publications may depend on your institution's access to the journals.)